Chikungunya Fever - Pipeline Review, H1 2018

  • ID: 4518513
  • Drug Pipelines
  • 100 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Ennaid Therapeutics LLC
  • Globavir Biosciences Inc
  • Indian Immunologicals Ltd
  • Moderna Therapeutics Inc
  • PaxVax Inc
  • Shionogi & Co Ltd
  • MORE
Chikungunya Fever - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Chikungunya Fever - Pipeline Review, H1 2018, provides an overview of the Chikungunya Fever (Infectious Disease) pipeline landscape.

Chikungunya is a viral disease transmitted to humans by the bite of infected Aedes aegypti mosquitoes. Chikungunya virus (CHIKV) is a member of the genus Alpha virus, in the family Togaviridae. Symptoms of Chikungunya includes debilitating arthralgia (joint pain), swelling of joints, stiffness of joints, myalgia (muscular pain), headache, fatigue (weakness), nausea, vomiting and rash and fever. Treatment includes use of NSAIDs.

Report Highlights:

This latest pipeline guide Chikungunya Fever - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Chikungunya Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chikungunya Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chikungunya Fever and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 6, 16 and 8 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 7 and 3 molecules, respectively.

Chikungunya Fever (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chikungunya Fever (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Chikungunya Fever (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chikungunya Fever (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chikungunya Fever (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chikungunya Fever (Infectious Disease)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chikungunya Fever (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chikungunya Fever (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Ennaid Therapeutics LLC
  • Globavir Biosciences Inc
  • Indian Immunologicals Ltd
  • Moderna Therapeutics Inc
  • PaxVax Inc
  • Shionogi & Co Ltd
  • MORE
Introduction

Report Coverage

Chikungunya Fever - Overview

Chikungunya Fever - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Chikungunya Fever - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Chikungunya Fever - Companies Involved in Therapeutics Development

Bharat Biotech International Ltd

Ennaid Therapeutics LLC

Etubics Corp

Globavir Biosciences Inc

Hawaii Biotech Inc

Indian Immunologicals Ltd

Inovio Pharmaceuticals Inc

Integral Molecular Inc

Integrated BioTherapeutics Inc

Moderna Therapeutics Inc

Mymetics Corp

Paradigm Biopharmaceuticals Ltd

PaxVax Inc

Profectus BioSciences Inc

Shionogi & Co Ltd

Takeda Pharmaceutical Co Ltd

Themis Bioscience GmbH

Valneva SE

Vaxart Inc

Chikungunya Fever - Drug Profiles

(chikungunya + Zika) (bivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BBV-87 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chikungunya (viral like particles) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chikungunya (virus like particle) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chikungunya vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chikungunya vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chikungunya vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chikungunya vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chikungunya vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chikungunya vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chikungunya vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chikungunya vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chikungunya vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chikungunya vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chikungunya vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chikungunya vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CIL-15001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GBV-006 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Chikungunya - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HSRx-431 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMCKV-063 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies for Chikungunya - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies for Equine Encephalitis and Chikungunya - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit CHIKV E2 for Chikungunya - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mRNA-1388 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mRNA-1944 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MV-CHIK - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pentosan polysulfate sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides for Infectious Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SCV-1002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SCV-305 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit NS4 for Chikungunya Fever - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Chikungunya - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Chikungunya - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Chikungunya Fever - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Chikungunya Fever - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Infectious Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SVIR-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides for Chikungunya - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-507 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tatbeclin-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VLA-1553 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chikungunya Fever - Dormant Projects

Chikungunya Fever - Product Development Milestones

Featured News & Press Releases

Mar 27, 2018: World-first technology developed by Australian biotech company set to revolutionize global vaccine industry

Mar 13, 2018: VALNEVA Initiates Phase I Clinical Study to Evaluate Its Single-Shot Vaccine Candidate against Chikungunya

Nov 06, 2017: Themis to Present Phase 2 Interim Results for Chikungunya Vaccine Candidate at ASTMH 2017 Annual Meeting

Sep 05, 2017: Chikungunya Vaccine Development Towards Phase III Trials Boosted by Innovate UK

Jul 27, 2017: Themis Bioscience Starts Phase II Clinical Study in Endemic Area

Jun 05, 2017: Bharat Biotech Begins Phase I Trial of Chikungunya Vaccine

Jun 05, 2017: NIAID-Sponsored Trial of Experimental Chikungunya Vaccine Begins

Mar 07, 2017: The Australian Company Testing a Breakthrough Treatment for Ross River

Jan 09, 2017: Profectus BioSciences Bivalent Vaccine Protects Animals from Infection and Death After Exposure to Chikungunya or Zika Virus

Dec 19, 2016: UTMB researchers develop first chikungunya vaccine from virus that does not affect people

Aug 30, 2016: Hawaii Biotech Awarded Grant To Develop Chikungunya Virus Vaccine

Aug 25, 2016: Leading Chikungunya Vaccine in Clinical Trial Phase

Mar 22, 2016: Inovio’s DNA-based Monoclonal Antibody and DNA Vaccine Provide 100% Protection Against Lethal Chikungunya Virus Challenge in Preclinical Study

Mar 02, 2015: Themis Bioscience’s Chikungunya Vaccine Study Results Published in The Lancet Infectious Diseases

Dec 10, 2014: Integral Molecular identifies potent inhibitory antibodies against Chikungunya virus

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Chikungunya Fever, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Chikungunya Fever - Pipeline by Bharat Biotech International Ltd, H1 2018

Chikungunya Fever - Pipeline by Ennaid Therapeutics LLC, H1 2018

Chikungunya Fever - Pipeline by Etubics Corp, H1 2018

Chikungunya Fever - Pipeline by Globavir Biosciences Inc, H1 2018

Chikungunya Fever - Pipeline by Hawaii Biotech Inc, H1 2018

Chikungunya Fever - Pipeline by Indian Immunologicals Ltd, H1 2018

Chikungunya Fever - Pipeline by Inovio Pharmaceuticals Inc, H1 2018

Chikungunya Fever - Pipeline by Integral Molecular Inc, H1 2018

Chikungunya Fever - Pipeline by Integrated BioTherapeutics Inc, H1 2018

Chikungunya Fever - Pipeline by Moderna Therapeutics Inc, H1 2018

Chikungunya Fever - Pipeline by Mymetics Corp, H1 2018

Chikungunya Fever - Pipeline by Paradigm Biopharmaceuticals Ltd, H1 2018

Chikungunya Fever - Pipeline by PaxVax Inc, H1 2018

Chikungunya Fever - Pipeline by Profectus BioSciences Inc, H1 2018

Chikungunya Fever - Pipeline by Shionogi & Co Ltd, H1 2018

Chikungunya Fever - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018

Chikungunya Fever - Pipeline by Themis Bioscience GmbH, H1 2018

Chikungunya Fever - Pipeline by Valneva SE, H1 2018

Chikungunya Fever - Pipeline by Vaxart Inc, H1 2018

Chikungunya Fever - Dormant Projects, H1 2018

List of Figures

Number of Products under Development for Chikungunya Fever, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Bharat Biotech International Ltd
  • Ennaid Therapeutics LLC
  • Etubics Corp
  • Globavir Biosciences Inc
  • Hawaii Biotech Inc
  • Indian Immunologicals Ltd
  • Inovio Pharmaceuticals Inc
  • Integral Molecular Inc
  • Integrated BioTherapeutics Inc
  • Moderna Therapeutics Inc
  • Mymetics Corp
  • Paradigm Biopharmaceuticals Ltd
  • PaxVax Inc
  • Profectus BioSciences Inc
  • Shionogi & Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • Themis Bioscience GmbH
  • Valneva SE
  • Vaxart Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll